MX9700574A - Metodo para establecer la secrecion de estrogeno tonico ovarico para regimenes terapeuticos prolongados. - Google Patents
Metodo para establecer la secrecion de estrogeno tonico ovarico para regimenes terapeuticos prolongados.Info
- Publication number
- MX9700574A MX9700574A MX9700574A MX9700574A MX9700574A MX 9700574 A MX9700574 A MX 9700574A MX 9700574 A MX9700574 A MX 9700574A MX 9700574 A MX9700574 A MX 9700574A MX 9700574 A MX9700574 A MX 9700574A
- Authority
- MX
- Mexico
- Prior art keywords
- gnrh antagonist
- establishment
- therapeutic regimens
- estrogen
- gonadal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un régimen para el manejo terapéutico de una condicion dependiente gonadal-esteroide en un mamífero constituye la reduccion del suministro de estrogeno del mismo por medio de la administracion de un antagonista de GnRH en una cantidad efectiva para inhibir la proliferacion de tejido endometrial sin detener substancialmente la produccion de estrogeno endogeno. Un método para determinar se el suministro de estrogeno reducido en un individuo es tal que la concentracion de estradiol ha sido suprimida hasta un nivel optimizado apropiado para el manejo terapéutico de la condicion dependiente gonadal-esteroide tal como endometriosis en ese individuo mediante la administracion de un antagonista de GnRH a un nivel de dosis dado involucra la titulacion de la dosis, por ejemplo, al conducir una prueba de estimulacion con progesterona y dosis de régimen optimas de un antagonista de GnRH.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27959394A | 1994-07-22 | 1994-07-22 | |
| US08/467,860 US5658884A (en) | 1994-07-22 | 1995-06-06 | Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens |
| PCT/US1995/008996 WO1996003138A1 (en) | 1994-07-22 | 1995-07-18 | Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX9700574A true MX9700574A (es) | 1997-12-31 |
Family
ID=26959766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9700574A MX9700574A (es) | 1994-07-22 | 1995-07-18 | Metodo para establecer la secrecion de estrogeno tonico ovarico para regimenes terapeuticos prolongados. |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP0769956B1 (es) |
| JP (1) | JP3138477B2 (es) |
| CN (1) | CN1137722C (es) |
| AP (1) | AP775A (es) |
| AT (1) | ATE190494T1 (es) |
| AU (1) | AU691952B2 (es) |
| BG (1) | BG63363B1 (es) |
| BR (1) | BR9508718A (es) |
| CA (1) | CA2195745C (es) |
| CY (1) | CY2228B1 (es) |
| CZ (1) | CZ291803B6 (es) |
| DE (1) | DE69515666T2 (es) |
| DK (1) | DK0769956T3 (es) |
| EE (1) | EE03515B1 (es) |
| ES (1) | ES2145286T3 (es) |
| FI (1) | FI970244A (es) |
| GR (1) | GR3033590T3 (es) |
| HU (1) | HU218910B (es) |
| IL (1) | IL114655A (es) |
| IS (1) | IS4413A (es) |
| LV (1) | LV11823B (es) |
| MX (1) | MX9700574A (es) |
| NO (1) | NO970257L (es) |
| NZ (1) | NZ290554A (es) |
| OA (1) | OA10730A (es) |
| PT (1) | PT769956E (es) |
| RU (1) | RU2181598C2 (es) |
| SK (1) | SK282118B6 (es) |
| WO (1) | WO1996003138A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8173592B1 (en) | 1999-03-31 | 2012-05-08 | Zentaris Ivf Gmbh | Method for a programmed controlled ovarian stimulation protocol |
| UA73956C2 (en) * | 1999-09-23 | 2005-10-17 | Zentaris Gmbh | Method for therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction due to extrauterine proliferation of endometrial tissue |
| DE10137174A1 (de) * | 2001-07-31 | 2003-02-13 | Zentaris Ag | Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität |
| GB0616111D0 (en) * | 2006-06-16 | 2006-09-20 | Ardana Bioscience Ltd | Agents, methods and uses |
| EP2095818A1 (en) | 2008-02-29 | 2009-09-02 | AEterna Zentaris GmbH | Use of LHRH antagonists at non-castrating doses |
| EP2307040B1 (en) * | 2008-05-29 | 2015-09-09 | Isr Immune System Regulation Ab | Use of gnrh and sex hormones for treating viral disease, in particular hiv/aids |
| ES2753539T3 (es) * | 2015-05-18 | 2020-04-13 | Nerre Therapeutics Ltd | Antagonista del receptor NK-1/NK-3 para el tratamiento de los sofocos |
| EP3560555A1 (en) * | 2018-04-26 | 2019-10-30 | LifeArc | A composition for treating one or more estrogen related diseases |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5171835A (en) * | 1988-10-21 | 1992-12-15 | The Administrators Of The Tulane Educational Fund | LHRH antagonists |
| US5169932A (en) * | 1989-10-30 | 1992-12-08 | The Salk Institute For Biological Studies | Gnrh analogs |
| US5211952A (en) * | 1991-04-12 | 1993-05-18 | University Of Southern California | Contraceptive methods and formulations for use therein |
| ZA924811B (en) * | 1991-06-28 | 1993-12-29 | Endorecherche Inc | Controlled release systems and low dose androgens |
| US5681817A (en) * | 1994-02-04 | 1997-10-28 | The Medical College Of Hampton Roads | Treatment of ovarian estrogen dependent conditions |
| US5407955A (en) * | 1994-02-18 | 1995-04-18 | Eli Lilly And Company | Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease |
-
1995
- 1995-07-18 IL IL11465595A patent/IL114655A/xx not_active IP Right Cessation
- 1995-07-18 HU HU9700046A patent/HU218910B/hu not_active IP Right Cessation
- 1995-07-18 EE EE9700208A patent/EE03515B1/xx not_active IP Right Cessation
- 1995-07-18 BR BR9508718A patent/BR9508718A/pt not_active Application Discontinuation
- 1995-07-18 CA CA002195745A patent/CA2195745C/en not_active Expired - Lifetime
- 1995-07-18 NZ NZ290554A patent/NZ290554A/xx not_active IP Right Cessation
- 1995-07-18 EP EP95927228A patent/EP0769956B1/en not_active Revoked
- 1995-07-18 MX MX9700574A patent/MX9700574A/es unknown
- 1995-07-18 PT PT95927228T patent/PT769956E/pt unknown
- 1995-07-18 CZ CZ1997150A patent/CZ291803B6/cs not_active IP Right Cessation
- 1995-07-18 DE DE69515666T patent/DE69515666T2/de not_active Revoked
- 1995-07-18 WO PCT/US1995/008996 patent/WO1996003138A1/en not_active Application Discontinuation
- 1995-07-18 JP JP08505816A patent/JP3138477B2/ja not_active Expired - Lifetime
- 1995-07-18 SK SK70-97A patent/SK282118B6/sk not_active IP Right Cessation
- 1995-07-18 AT AT95927228T patent/ATE190494T1/de not_active IP Right Cessation
- 1995-07-18 ES ES95927228T patent/ES2145286T3/es not_active Expired - Lifetime
- 1995-07-18 CN CNB951951696A patent/CN1137722C/zh not_active Expired - Fee Related
- 1995-07-18 AU AU31320/95A patent/AU691952B2/en not_active Expired
- 1995-07-18 AP APAP/P/1997/000913A patent/AP775A/en active
- 1995-07-18 DK DK95927228T patent/DK0769956T3/da active
- 1995-07-18 RU RU97102759/14A patent/RU2181598C2/ru not_active IP Right Cessation
-
1997
- 1997-01-13 OA OA60952A patent/OA10730A/en unknown
- 1997-01-14 IS IS4413A patent/IS4413A/is unknown
- 1997-01-21 NO NO970257A patent/NO970257L/no not_active Application Discontinuation
- 1997-01-21 FI FI970244A patent/FI970244A/fi not_active Application Discontinuation
- 1997-01-21 BG BG101158A patent/BG63363B1/bg unknown
- 1997-02-26 LV LVP-97-30A patent/LV11823B/en unknown
-
2000
- 2000-05-31 GR GR20000401285T patent/GR3033590T3/el not_active IP Right Cessation
-
2001
- 2001-07-26 CY CY0100017A patent/CY2228B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LV11782A (lv) | Lidzeklis no oinicu estrogena atkariga stavokla arstesanai | |
| Mahesh et al. | Interaction between ovarian and adrenal steroids in the regulation of gonadotropin secretion | |
| Bonavera et al. | Evidence in support of nitric oxide (NO) involvement in the cyclic release of prolactin and LH surges | |
| DE69532927D1 (de) | Cyclophasiges hormonverfahren das antiprogestin und progestin enthält | |
| Kauppila et al. | Hypoprolactinemia and ovarian function | |
| MX9700574A (es) | Metodo para establecer la secrecion de estrogeno tonico ovarico para regimenes terapeuticos prolongados. | |
| Brann et al. | Excitatory amino acid regulation of gonadotropin secretion: modulation by steroid hormones | |
| Celio et al. | Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study | |
| Jackson | Effect of adrenergic blocking drugs on secretion of luteinizing hormone in the ovariectomized ewe | |
| JO1879B1 (en) | Consolidation of the secretion of ovarian estrogen for prolonged treatment regimens | |
| Ferland et al. | Role of sex steroids on LH and FSH secretion in the rat | |
| Redding et al. | Investigation of the combination of the agonist D‐Trp‐6‐LH‐RH and the antiandrogen flutamide in the treatment of Dunning R‐3327H prostate cancer model | |
| Naik et al. | Evidence for a pituitary site of gonadal steroid stimulation of GnRH receptors in female mice | |
| Rowe et al. | Central administration of the neurotensin receptor antagonist, SR48692, modulates diurnal and stress-related hypothalamic-pituitary-adrenal activity | |
| YU55403A (sh) | Upotreba antigestagena za inhibiciju ubrzanog endometrijumskog sazrevanja tokom lečenja neplodnosti | |
| RU97102759A (ru) | Восстановление тонической секреции эстрогена из яичников для продолжительных схем лечения | |
| Labrie et al. | Inhibitory effects of treatment with LHRH or its agonists on ovarian receptor levels and function | |
| Roseff et al. | Accelerated dissolution of luteal-endometrial integrity by the administration of antagonists of gonadotropin-releasing hormone and progesterone to late-luteal phase women | |
| Nishino et al. | Antitumor effect of a specific aromatase inhibitor, 1-methyl-androsta-1, 4-diene-3, 17-dione (atamestane), in female rats bearing DMBA-induced mammary tumors | |
| Crosignani et al. | Human prolactin release induced by follicle stimulating hormone, luteinizing hormone and human chorionic gonadotrophin | |
| Sutherland et al. | Ovariectomized does do not require progesterone priming for oestrous behaviour | |
| ADELSON et al. | Effects of gonadotropin-releasing hormone analogues on ovarian epithelial tumors | |
| Ahmann et al. | Adrenal steroid levels in castrated men with prostatic carcinoma treated with aminoglutethimide plus hydrocortisone | |
| CA2428249A1 (en) | Combination therapy for estrogen-dependent disorders | |
| Tonetta et al. | Effect of cyanoketone on follicle-stimulating hormone (FSH) induction of receptors for FSH in granulosa cells of the rat |